Kodiak Sciences (KOD) Income towards Parent Company (2017 - 2026)
Kodiak Sciences (KOD) posted Income towards Parent Company of -$522.5 million for Q1 2026, down 35.73% on a QoQ basis from -$385.0 million in Q4 2025, and down 780.19% year-over-year from $76.8 million in Q1 2025.
Kodiak Sciences (KOD) Income towards Parent Company (2017 - 2026) Analysis & Trends
Kodiak Sciences' Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$522.5 million for Q1 2026.
- Quarterly Income towards Parent Company fell 780.19% year-over-year to -$522.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 512.96% YoY) and the FY2025 annual result came in at -$558.2 million, down 31.98% from the prior year.
- Income towards Parent Company was -$522.5 million for Q1 2026 at Kodiak Sciences, down from -$385.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$44.8 million in Q1 2024 and bottomed at -$522.5 million in Q1 2026.
- A 5-year average of -$121.2 million and a median of -$71.1 million in 2022 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company soared 84.3% — and 2026, when it plunged 780.19%.
- Kodiak Sciences' Income towards Parent Company stood at -$71.1 million in 2022, then advanced by 15.04% to -$60.4 million in 2023, then grew by 25.54% to -$44.9 million in 2024, then tumbled by 756.48% to -$385.0 million in 2025, then sank by 35.73% to -$522.5 million in 2026.
- Business Quant data shows KOD's Income towards Parent Company at -$522.5 million in Q1 2026, -$385.0 million in Q4 2025, and -$228.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Kodiak Sciences | 2.62 Bn | 2.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -522.55 Mn |
| Dec 31, 2025 | -384.98 Mn |
| Sep 30, 2025 | -228.01 Mn |
| Jun 30, 2025 | -60.04 Mn |
| Mar 31, 2025 | -59.37 Mn |
| Dec 31, 2024 | -44.95 Mn |
| Sep 30, 2024 | -45.11 Mn |
| Jun 30, 2024 | -45.62 Mn |
| Mar 31, 2024 | -44.77 Mn |
| Dec 31, 2023 | -60.36 Mn |
| Sep 30, 2023 | -50.31 Mn |
| Jun 30, 2023 | -85.17 Mn |
| Mar 31, 2023 | -74.50 Mn |
| Dec 31, 2022 | -71.05 Mn |
| Sep 30, 2022 | -83.64 Mn |
| Jun 30, 2022 | -97.02 Mn |
| Mar 31, 2022 | -102.26 Mn |
| Dec 31, 2021 | -93.03 Mn |
| Sep 30, 2021 | -498.78 Mn |
| Jun 30, 2021 | -502.79 Mn |